Vijay Samant
Director/Board Member bei Xiconic Pharmaceuticals LLC
Profil
Vijay B.
Samant currently works at Xiconic Pharmaceuticals LLC, as Director.
Mr. Samant also formerly worked at Vical, Inc., as President, Chief Executive Officer & Director from 2000 to 2019, AmpliPhi Biosciences Corp., as Independent Director from 2015 to 2019, Materials Management, Inc., as Executive Director, BioMarin Pharmaceutical, Inc., as Director from 2002 to 2004, Aeras Global TB Vaccine Foundation, as Director in 2010, Raptor Pharmaceuticals Corp., as Director from 2011 to 2014, Horizon Pharmaceutical LLC, as Independent Director from 2011 to 2014, Fresh Tracks Therapeutics, Inc., as Independent Director from 2000 to 2023, Merck & Co., Inc., as Chief Operating Officer-Vaccine Division from 1998 to 2000, National Foundation for Infectious Diseases, as Trustee from 2003 to 2012, and International Vaccine Institute, as Trustee from 2011 to 2012.
Mr. Samant received his graduate degree in 1977 from The Trustees of Columbia University in The City of New York, undergraduate degree in 1975 from the University of Mumbai, and Masters Business Admin degree in 1983 from MIT Sloan School of Management.
Aktive Positionen von Vijay Samant
| Unternehmen | Position | Beginn |
|---|---|---|
| Xiconic Pharmaceuticals LLC | Director/Board Member | - |
Ehemalige bekannte Positionen von Vijay Samant
| Unternehmen | Position | Ende |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Director/Board Member | 02.10.2023 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Executive Officer | 01.08.2019 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director/Board Member | 01.01.2019 |
| RAPTOR PHARMACEUTICAL CORP | Director/Board Member | 28.07.2014 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Director/Board Member | 01.01.2014 |
Ausbildung von Vijay Samant
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| University of Mumbai | Undergraduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Materials Management, Inc.
 Materials Management, Inc. Miscellaneous Commercial ServicesCommercial Services Materials Management, Inc. engages in metal management services. The firm''s services include planning and marketing, risk management and financial services, inventory and metals control, finance and banking, regulatory compliance and trouble-shooting and litigation support. The company was founded by Mike Riess and is headquartered in Greenwich, CT. | Commercial Services |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
National Foundation for Infectious Diseases
 National Foundation for Infectious Diseases Miscellaneous Commercial ServicesCommercial Services National Foundation for Infectious Diseases engages in providing information and resources about vaccines recommended for adults, adolescents and children, including links to updated Center for Disease Control and Prevention (CDC) Immunization Schedules and a Fact Sheet about how vaccines work. The company is headquartered in Bethesda, MD. | Commercial Services |
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Commercial Services |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
| Xiconic Pharmaceuticals LLC |
